The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 24, 2021
Filed:
Oct. 05, 2018
Applicant:
Angimmune, Llc, Bethesda, MD (US);
Inventor:
David M. Neville, Bethesda, MD (US);
Assignee:
ANGIMMUNE, LLC, Bethesda, MD (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 47/68 (2017.01); C07K 16/28 (2006.01); A61K 38/16 (2006.01); C07K 16/30 (2006.01); A61P 35/00 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2809 (2013.01); A61K 38/164 (2013.01); A61K 39/0011 (2013.01); A61K 39/3955 (2013.01); A61K 47/6829 (2017.08); A61K 47/6849 (2017.08); A61K 47/6879 (2017.08); A61P 35/00 (2018.01); C07K 16/30 (2013.01); A61K 2039/505 (2013.01); A61K 2039/545 (2013.01); C07K 2317/35 (2013.01); C07K 2317/622 (2013.01); C07K 2317/73 (2013.01); C07K 2319/00 (2013.01); Y02A 50/30 (2018.01);
Abstract
Methods of modulating the immune systems of patients suffering from cancers that do not bear, or do not uniformly bear, surface CD3 are provided. The methods involve administering an anti-CD3 immunotoxin (e.g. A-dmDT390-bisFv(UCHT1)), to the patient so as to cause the patient's immune system to recognize and destroy non-CD3 cancer cells.